A101: Atypical, anti-viral IgG4 antibody responses after SARS-CoV-2 mRNA vaccination
FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.04.2023
End date : 30.09.2025
Project details
Scientific Abstract
Recently, we identified atypical, antiviral IgG4 responses after immunizations with a SARS-CoV-2 mRNA vaccine. Since IgG4 responses are considered as anti-infammatory and rather tolerogenic, the impact of this type of antibody response on preventing viral infections or disease will be elucidated. Whether antigen re-exposures in form of infections or boost immunization will further shift the SARS-CoV-2 response towards IgG4 will be analysed as well as potential underlying mechanisms.
Involved:
Matthias Tenbusch
Project Leader
Kilian Schober
Project Member
Moritz Leppkes
Project Member
Thomas Winkler
Project Member
Contributing FAU Organisations:
Professur für Genbasierte Immunisierungsverfahren
Institute of Microbiology – Clinical Microbiology, Immunology and Hygiene
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Professur für Genetik
Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology
Medizinische Fakultät
